Racura Oncology (FN3) Stock Overview
Operates as a Phase 3 clinical biopharmaceutical company for cancer care. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
FN3 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Racura Oncology Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$1.31 |
| 52 Week High | AU$2.64 |
| 52 Week Low | AU$0.60 |
| Beta | 0.81 |
| 1 Month Change | -12.08% |
| 3 Month Change | -14.38% |
| 1 Year Change | 106.30% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 18.12% |
Recent News & Updates
Recent updates
Shareholder Returns
| FN3 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -3.7% | 2.7% | 1.7% |
| 1Y | 106.3% | -5.8% | 2.6% |
Return vs Industry: FN3 exceeded the German Biotechs industry which returned -5.7% over the past year.
Return vs Market: FN3 exceeded the German Market which returned 1.1% over the past year.
Price Volatility
| FN3 volatility | |
|---|---|
| FN3 Average Weekly Movement | 10.3% |
| Biotechs Industry Average Movement | 8.4% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in DE Market | 12.8% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: FN3's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: FN3's weekly volatility has decreased from 25% to 10% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | n/a | Daniel Tillett | www.racuraoncology.com |
Racura Oncology Ltd operates as a Phase 3 clinical biopharmaceutical company for cancer care. Its lead asset is RCDS1 (E,E-bisantrene), a small molecule anticancer agent that primarily functions through G4-DNA & RNA binding to potent inhibition of the cancer growth regulator MYC. The company is advancing a proprietary formulation of RCDS1 (RC220) to address the unmet needs of patients across various oncology indications with Phase 3 clinical programs in acute myeloid leukaemia, Phase 1a/b program in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm NSCLC), and a Phase 1a/b program in combination with the anthracycline doxorubicin.
Racura Oncology Ltd Fundamentals Summary
| FN3 fundamental statistics | |
|---|---|
| Market cap | €269.94m |
| Earnings (TTM) | -€5.68m |
| Revenue (TTM) | €2.10m |
Is FN3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FN3 income statement (TTM) | |
|---|---|
| Revenue | AU$3.48m |
| Cost of Revenue | AU$511.07k |
| Gross Profit | AU$2.97m |
| Other Expenses | AU$12.35m |
| Earnings | -AU$9.39m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.048 |
| Gross Margin | 85.30% |
| Net Profit Margin | -270.04% |
| Debt/Equity Ratio | 0% |
How did FN3 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/02 10:11 |
| End of Day Share Price | 2026/07/02 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Racura Oncology Ltd is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Independent Investment Research (Aust.) Pty Ltd |
| Chris Kallos | MST Financial Services Pty Limited |